Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TELLOMAK: IPH4102 in Advanced T-cell Lymphoma
NCT03902184Phase 2Completed
- Sponsor
- Innate Pharma
- Start
- May 2019
- Primary completion
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, open-label trial of lacutamab in Sézary syndrome (SS) and mycosis fungoides (MF) (4 cohorts), sponsored by Innate Pharma. Primary endpoint: Objective Response Rate up to 2 years. Started May 2019; status: completed.
02
Drugs
lacutamab
03
Conditions
Sézary syndrome (SS)mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT03902184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03902184.